Search - tctmd.com

Displaying 821 - 840 of 900

Sort: Relevancy | Date

News Daily News

Ischemic Preconditioning Limits Contrast-Induced Kidney Damage

Caitlin E. Cox

July 02, 2012

News Daily News

PLATO Subanalysis: Ticagrelor Cost-Effective in ACS Patients

June 26, 2012

News Daily News

Antiplatelet Shows Promise for Secondary Prevention in PAD

Caitlin E. Cox

June 25, 2012

News Daily News

Dramatic Increase Seen Nationwide in Advanced Imaging, Radiation Exposure

L.A. McKeown

June 13, 2012

News Daily News

Renal Denervation Part 2: How Far, How Fast for Promising New Therapy?

June 12, 2012

News Daily News

VA Registry Finds Long-term Benefit from Clopidogrel Beyond 12 Months

Caitlin E. Cox

June 11, 2012

News Daily News

Renal Denervation: Treatment for Hypertension Captures Interventional Spotlight

June 05, 2012

News Daily News

Registry Finds Overall Decrease in Post-PCI Bleeding but Not in STEMI

Caitlin E. Cox

June 01, 2012

News Daily News

Several Factors Behind False-Positive STEMI Activations

Yael L. Maxwell

May 09, 2012

News Daily News

FDA Label Change Fails to Stem Uncertainty Over PPI Use with Clopidogrel

Caitlin E. Cox

May 09, 2012

News Features

FDA Label Change Fails to Stem Uncertainty Over PPI Use with Clopidogrel

Caitlin E. Cox

May 07, 2012

News Daily News

CT Scans Cause Delays in Care When Performed Prior to Primary PCI

Jason Kahn

May 04, 2012

News Daily News

ROCKET AF: Stopping Rivaroxaban or Warfarin Equally Harmful in A-fib Patients

Caitlin E. Cox

April 26, 2012

News Daily News

JAMA Letters Continue Debate Over Genotype, Clopidogrel Response

Caitlin E. Cox

April 12, 2012

News Daily News

CHARISMA Genetics Analysis: CYP2C19 Variants Show Little Clinical Impact

April 10, 2012

News Daily News

Aggressive Statin Therapy Lowers Lipid Burden in Obstructive Lesions

April 05, 2012

News Conference News ACC 2012

ASCERT: Long-term Survival Advantage with CABG in Multivessel Disease

Yael L. Maxwell

March 27, 2012

News Conference News ACC 2012

RESOLUTE: Zotarolimus-Eluting Stent Fares Well at 2 Years

March 26, 2012

News Conference News ACC 2012

New Antiplatelet Agent Vorapaxar Shows Promise, But At the Expense of Bleeding

L.A. McKeown

March 24, 2012

News Daily News

African-Americans Have Higher Bleeding Rates After Reperfusion for STEMI

L.A. McKeown

March 20, 2012

Advertisement

Ischemic Preconditioning Limits Contrast-Induced Kidney Damage

PLATO Subanalysis: Ticagrelor Cost-Effective in ACS Patients

Antiplatelet Shows Promise for Secondary Prevention in PAD

Dramatic Increase Seen Nationwide in Advanced Imaging, Radiation Exposure

Renal Denervation Part 2: How Far, How Fast for Promising New Therapy?

VA Registry Finds Long-term Benefit from Clopidogrel Beyond 12 Months

Renal Denervation: Treatment for Hypertension Captures Interventional Spotlight

Registry Finds Overall Decrease in Post-PCI Bleeding but Not in STEMI

Several Factors Behind False-Positive STEMI Activations

FDA Label Change Fails to Stem Uncertainty Over PPI Use with Clopidogrel

FDA Label Change Fails to Stem Uncertainty Over PPI Use with Clopidogrel

CT Scans Cause Delays in Care When Performed Prior to Primary PCI

ROCKET AF: Stopping Rivaroxaban or Warfarin Equally Harmful in A-fib Patients

JAMA Letters Continue Debate Over Genotype, Clopidogrel Response

CHARISMA Genetics Analysis: CYP2C19 Variants Show Little Clinical Impact

Aggressive Statin Therapy Lowers Lipid Burden in Obstructive Lesions

ASCERT: Long-term Survival Advantage with CABG in Multivessel Disease

RESOLUTE: Zotarolimus-Eluting Stent Fares Well at 2 Years

New Antiplatelet Agent Vorapaxar Shows Promise, But At the Expense of Bleeding

African-Americans Have Higher Bleeding Rates After Reperfusion for STEMI

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content